Ameriprise
XENE icon

Ameriprise’s Xenon Pharmaceuticals XENE Stock Holding History

Ameriprise’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.59M Sell
78,905
-30,639
-28% -$1.41M ﹤0.01% 2487
2025
Q4 		$4.91M Buy
109,544
+11,977
+12% +$503K ﹤0.01% 2448
2025
Q3 		$3.92M Sell
97,567
-24,459
-20% -$861K ﹤0.01% 2606
2025
Q2 		$3.82M Buy
122,026
+18,402
+18% +$600K ﹤0.01% 2556
2025
Q1 		$3.48M Buy
103,624
+11,274
+12% +$428K ﹤0.01% 2568
2024
Q4 		$3.62M Buy
92,350
+25,967
+39% +$1.07M ﹤0.01% 2585
2024
Q3 		$2.61M Buy
+66,383
New +$2.68M ﹤0.01% 2770
2023
Q1 		– Sell
-22,626
Closed -$891K – 4041
2022
Q4 		$891K Sell
22,626
-18,518
-45% -$674K ﹤0.01% 3191
2022
Q3 		$1.49M Sell
41,144
-10,032
-20% -$361K ﹤0.01% 2921
2022
Q2 		$1.56M Sell
51,176
-6,756
-12% -$204K ﹤0.01% 2918
2022
Q1 		$1.77M Sell
57,932
-389
-0.7% -$11.6K ﹤0.01% 2962
2021
Q4 		$1.82M Buy
58,321
+43,621
+297% +$1.3M ﹤0.01% 2986
2021
Q3 		$225K Buy
+14,700
New +$255K ﹤0.01% 3675

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise's XENE Position: Q1 2026 in Review

Ameriprise reduced its Xenon Pharmaceuticals (XENE) stake by 28% in Q1 2026, selling an estimated $1.41M and leaving 78,905 shares worth $4.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2487.

Ameriprise first reported a position in XENE in Q3 2021 and has held it in 13 quarters since. The position peaked at $4.91M in Q4 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Ameriprise held 78,905 shares of Xenon Pharmaceuticals worth $4.59M as of Q1 2026.
  • Ameriprise sold 30,639 Xenon Pharmaceuticals shares in Q1 2026, an estimated $1.41M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2487 holding.
  • Ameriprise first reported a position in Xenon Pharmaceuticals in Q3 2021 and has held it in 13 quarters since.
  • Ameriprise's Xenon Pharmaceuticals position peaked at $4.91M in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.